Impact of the 719Arg Variant of KIF6 and Major Cardiovascular Events on Patients who Received Statins: A Systematic Review and Meta-Analysis

摘要

Purpose: The purpose of this study was to determine the relationship between Kinesin like protein 6(KIF6) gene Trp719Arg and major cardiovascular events (MACEs) risk in subjects who received statin therapy.Methods: PubMed, EmBase, and the Cochrane Library were searched from inception through September 2017.The selected studies evaluated the association of Trp719Arg with MACEs in individuals who received statins.Relative risk (RR) and 95% confidence interval (CI) were used to evaluate the effect of statin therapy on MACEsin subjects carrying polymorphisms, and the odds ratio (OR) and 95% CI were used to evaluate the relationshipbetween Trp719Arg and MACE risk in individuals who received statins, using the random-effects model.Results: Seven studies were included (N=48,885). Overall, we found that statin therapy significantly reduced therisk for MACEs in subjects carrying ArgArg (RR: 0.79; 95% CI: 0.69-0.90; P=0.001), ArgTrp (RR: 0.71; 95%CI: 0.60 -0.83; P<0.001), ArgArg+ArgTrp (RR: 0.71; 95% CI: 0.63 -0.81; P<0.001), and TrpTrp (RR: 0.79; 95%CI: 0.73-0.85; P<0.001). Furthermore, there was no significant difference between subjects carrying ArgArg andthose carrying TrpTrp (OR: 1.11; 95% CI: 0.92-1.34; P=0.265). However, ArgTrp (OR: 1.29; 95% CI: 1.07-1.55;P=0.007) and ArgArg+ArgTrp (OR: 1.26; 95% CI: 1.05-1.51; P=0.012) were associated with an increased riskfor MACEs when compared with TrpTrp.Conclusions: Statin therapy significantly reduced the risk for MACEs in subjects carrier specific KIF6 geneTrp719Arg polymorphisms. Further, subjects carrying ArgTrp or ArgArg+ArgTrp had a greater incidence ofMACEs as compared with TrpTrp when they received statins.